研究单位:[1]Eastern Hepatobiliary Surgery Hospital, Eastern Hepatobiliary Surgery Hospital[2]Tongji Hospital,Huazhong University of Science & Technology华中科技大学同济医学院附属同济医院[3]Huazhong University of Science and Technology[4]Shanghai Zhongshan Hospital
Using the subject with hepatocellular carcinoma in the conventional therapy to evaluate the efficacy and safety of ginsenoside Rg3 (20mg BID) and placebo in prevention and treatment of postoperative recurrence of liver cancer,respectively